Analysis of the clinical efficacy of vaccination against pneumococcal infection in patients with chronic obstructive pulmonary disease and bronchiectasis

Abstract

The article presents data on the analysis of the clinical efficacy of vaccination against pneumococcal infection in patients with chronic obstructive pulmonary disease (COPD) in combination with bronchiectasis during a 5 years follow-up period. Materials and methods. The study included male patients (n=62) with COPD in combination with bronchiectasis. The primary endpoints were changes the severity of dyspnea using mMRS score, forced expiratory volume in 1 second (FEV1), number of exacerbations of COPD, hospitalizations, and a rate of pneumonia. The prognostic indices BODE, DOSE, ADO were also calculated. 13-valent conjugate pneumococcal vaccine PCV-13 were used for vaccination. Results. It has been established that when vaccination is included in the management plan for COPD patients with bronchiectasis, the severity of dyspnea decreases, the lung function stabilize not only in the short-term, but also for at 5-years follow-up. Vaccination with PCV-13 significantly reduce number of exacerbations, a rate of pneumonia and hospitalizations during the 5-years follow-up. Vaccination of pneumococcal infection improves the quality of life and prognosis for COPD patients with bronchiectasis. Conclusion. Vaccination of pneumococcal infection in patients with COPD and bronchiectasis can reduce the number of exacerbations, incidence of pneumonia and the number of hospitalizations, improve the prognosis and survival of patients using PCV-13 by maintaining efficacy for 5 years of follow-up.

Keywords

• chronic obstructive pulmonary disease
• bronchiectasis
• vaccination